LH

Lewis H. Bender

Founder, President, Chief Executive Officer

Intensity Therapeutics

Therapeutic Areas

Intensity Therapeutics Pipeline

DrugIndicationPhase
INT230-6Metastatic Soft Tissue SarcomasPhase 2/3